Introduction
In recent years, selection of lung cancer treatment has become increasingly sophisticated. Whereas the choice of conventional cytotoxic chemotherapy is largely based on cancer stage and histology, the selection of newer agents such as molecularly targeted therapies and immune checkpoint inhibitors often incorporates additional tumor biomarker testing. These predictive biomarkers increase therapeutic yield, limit unnecessary exposure to toxicity, and enhance treatment cost-effectiveness. 1 However, they also increase the complexity of care, requiring additional steps to acquire and analyze biospecimens. Nowadays, biomarker development often parallels drug development in lung cancer clinical research. The earliest clinical trials of a novel agent may include optional exploratory biomarkers to generate hypotheses for subsequent studies. Subsequently, required biomarker assessment may be incorporated as a stratification factor to determine clinical impact prospectively. As a last step, enrollment biomarkers are used to select patients up front for participation.
While predictive biomarkers provide the foundation of personalized or precision medicine, they have added to the complexities and costs of clinical research. 2 Independent of these considerations, clinical trial protocols have become more lengthy, and eligibility criteria more stringent. [3] [4] [5] [6] Even before tissue requirements were routinely incorporated into study protocols, less than 5% of adults with cancer in the United States participated in clinical trials. [7] [8] [9] This dismal statistic reflects trial availability, patient and provider preferences, and exclusion criteria. [10] [11] [12] [13] [14] [15] [16] [17] Additionally, biomarker requirements in lung cancer clinical trials may require intensive effort to obtain, process, analyze, and interpret in a short enough interval to be clinically acceptable in the setting of an advanced malignancy.
To determine the impact of biomarker requirements on staff effort and treatment intervals, we analyzed a recent cohort of patients with lung cancer enrolled onto clinical trials with mandatory or optional tissue requirements for biomarker analyses.
Methods
This study was conducted at the Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (UT Southwestern), located in Dallas, TX. The study overview was submitted to the UT Southwestern institutional review board before initiation. It was considered a quality improvement/quality assurance project and therefore did not require ongoing institutional review board oversight. Using research documents, electronic medical records, and archived communication records, we collected data for sequential patients enrolled from 2009 to 2016 onto lung cancer clinical trials with optional or mandatory tissue submission for biomarker studies. We did not include patients enrolled onto trials without optional or mandatory tissue submission. This time period was selected on the basis of record availability and on the completion of clinical screening processes. During this time period at UT Southwestern, electronic clinical trial records were maintained in the institutional Velos database. Velos eResearch (Velos, Fremont, CA, http://www. velos.com) is a study management tool used to help investigators manage the setup and day-to-day activities of human research studies. During this time, the institution used the EPIC electronic medical record (Verona, WI).
From these sources, we collected the following data: dates of consent, tissue request, shipping, results reporting, and treatment initiation; dates, content, and methods of communication related to tissue acquisition and analysis; nature of tissue requirement; type and location of archival tissue; and nature of biomarker analysis. In cases with multiple associated archival specimens, tissue type was categorized as the largest available (surgical > core > cytology/fine needle aspiration). Location of tissue was categorized as UT Southwestern or elsewhere. Nature of tissue requirement was categorized as required, requested if available, or optional. Type of biomarker analysis was categorized as exploratory, stratification, or enrollment. Cases with more than one type of biomarker analysis were categorized according to the most stringent category (enrollment > stratification > exploratory). Staff communications were recorded for each patient and described as follows: date, direction (incoming or outgoing), method (mail, phone, fax, or e-mail), and content (tissue request, status update, or documentation request). Communication data were obtained from records routinely kept by clinical research staff as part of a center effort to document and improve timeliness to enrollment and treatment.
Associations between case characteristics, clinical intervals, and number of staff communications were analyzed by statistical methods that do not depend on the presumption of distribution, such as Fisher's exact test, Wilcoxon 2-sample test, and KruskalWallis test. All reported P values are 2 sided. A P value less than .05 was considered to be statistically significant. All statistical calculations were performed by SAS 9.4 for Windows (SAS Institute, Cary, NC).
Results
We identified a total of 129 patients enrolled onto 19 lung cancer clinical trials with optional or mandatory tissue submission. Among these, 108 (84%) ultimately received study therapy. Patient characteristics are shown in Table 1 . Among the 19 clinical trials on which the patients were enrolled, 18 (95%) were for stage IV disease, and 12 (63%) were for second-line therapy or beyond.
Tissue disposition is shown in Table 2 . Whether or not tissue was submitted was significantly associated with trial tissue requirements. In cases for which tissue submission was optional, tissue was submitted in no cases, compared to 16% of cases for which it was requested if available and 87% of cases for which it was required (P < .001). Among 21 enrolled patients (16%) who never received study therapy, 5 (24%) did not for tissue-related reasons: inadequate tissue in 3 and negative enrollment biomarkers in 2. Figure 1 displays a schema of tissue acquisition and processing, as well as case disposition. In the overall study cohort, median time between consent and treatment initiation was 11 (interquartile range [IQR], 7-27) days. This interval was significantly associated with nature of biomarker analysis and tissue requirement (Table 3 ). In terms of individual process component intervals, the nature of Among cases for which tissue was requested (n ¼ 54), the total number of staff communications related to tissue acquisition and analysis was 240. Among these, 74 (31%) were incoming and 166 (69%) were outgoing; 11 (5%) were phone, 64 (27%) were fax, 78 (33%) were e-mail, 58 (24%) were mail, and 29 (12%) were unknown type. Communication content was categorized as follows: tissue request, 91 (38%); status update, 88 (37%); and documentation request, 61 (25%). Type of communication was associated with year of enrollment and tissue location. In 2009 to 2012, there were no e-mail communications, versus 38% in 2013 to 2016 (P ¼ .005). For cases with tissue located at UT Southwestern, 52% of communications occurred via e-mail, versus 18% of communications among cases with tissue located elsewhere (P < .001). Across all cases with requested tissue, the median number of communications was 3 (range, 0-10). Similar to consentetreatment intervals, the number of staff communications was significantly associated with nature of biomarker requirement. Median numbers of communications was 3 (IQR, 3-4) for cases with enrollment and stratification biomarkers and 0 (IQR, 0-1) for cases with exploratory biomarkers (P < .001). The association between case characteristics and number of communications is shown in Table 4 . 
Discussion
Sponsors, investigators, and clinicians involved in the design and conduct of cancer clinical trials face competing pressures. Given the intensive resource and time investment to activate and complete a study, there is a desire to optimize scientific yield. In the current era, this often implies an analysis of tumor molecular characteristics. In extreme instances, this may result in requests for biospecimens not only before treatment, but also at time of response and again at disease progression. At the same time, sponsors and investigators are facing pressures to limit resource utilization, contain costs, complete enrollment in a timely fashion, and provide efficient, quality care on protocol. The effect of tissue requirements on treatment delays has been reported previously. 2, 18 In the current analysis, we analyzed case characteristics associated with such delays, as well as impact on staff effort. Overall, we found that enrollment and stratification biomarkers result in greater treatment delay and staff effort than do exploratory biomarkers. This expected result reflects the biomarker role in treatment allocation and study flow. Enrollment and stratification biomarkers must be analyzed and reported before treatment assignment, whereas exploratory biomarker analyses are often performed later. The nature of the requirement also impacts research staff approach to biospecimen submission at our center. For mandatory requests, coordinators usually must address tissue requirements as part of the enrollment process. For optional tissue requests, research coordinators prioritize enrollment and start of study therapy, then subsequently address tissue requests. Somewhat surprisingly, the location of tumor tissue may not impact the consent-to-treatment interval or the total number of staff communications. The issue of tissue location (on vs. off-site) is particularly relevant to tertiary care centers, where patients may seek second opinions or clinical trial opportunities after undergoing initial diagnosis and staging at other facilities.
Over time, there was a nonsignificant trend in process intervals, as well as a significant increase in the number of staff communications. As more clinical trials use stratification or enrollment biomarkers, pressure from clinicians and patients to initiate study therapy may result in increased staff effort to complete the screening process as quickly as possible. That these staff communications take numerous and diverse forms (electronic, fax, telephone) attests to the required coordination and documentation of tissue-related tasks.
It is striking that when tumor tissue submission was optional, it was not sent for a single case. There are a number of plausible reasons for this. Such trials may selectively attract patients with inadequate tissue specimens. Alternatively, patients and clinicians may wish to retain as much tissue as possible, knowing that a future clinical trial or treatment decision may mandate tissue submission. Finally, aware of the intense effort associated with tissue acquisition and submission, study investigators and coordinators may be reluctant to pursue it if not required. Our findings, though extreme, are relatively consistent with the low proportion (generally about one-quarter) of cases providing optional tissue specimens in reported lung cancer clinical trials. 19, 20 How can trial sponsors, investigators, regulatory officials, and participating centers optimize the involvement and care of patients on clinical trials incorporating biomarker analyses? Biomarker prioritization, request of the minimal amount of tissue needed, and allowance of tissue prescreening (so biomarker analysis is completed before a patient requires new therapy) are a few basic approaches. Locally, oncologists can communicate with surgical, pulmonary medicine, and interventional radiology colleagues to convey the importance of more generous tissue specimens (eg, core or surgical biopsies rather than cytology/fine needle aspiration) as standard of care. Clinical teams can anticipate the need for tissue samples before a patient's initial consultation, thereby starting the process of acquisition as early as possible. Finally, the emergence of blood-and imaging-based biomarkers may obviate the need for tissue considerations in the future.
Our study has a number of limitations. Given the single-center setting, results may not be generalizable. For some data points, such as staff communication details and dates of intermediate steps in the consent-to-treatment initiation process, rates of missing data are relatively high. We do not have reasons for nonsubmission of tissue in the cases where it was not sent. The current analysis does not include patients enrolled onto clinical trials without optional or mandatory tissue submission. However, because optional tissue submission is addressed only after other screening and enrollment procedures are completed at our center, we believe that the optional tissue submission cases serve as an effective internal control population. Small sample size may underpower some of our analyses, such as timeline differences according to tissue location. Finally, the relatively small number of cases (eg, no cases in 2009-2012 had required biomarkers or enrollment/stratification biomarkers) prevents meaningful bivariate analyses to determine underlying reasons for the observed time trends.
In summary, tissue biomarker analysis plays a central and growing role in lung cancer clinical research. Biomarker requirements increase complexity of care, delays in treatment initiation, and staff effort. Given the host of other increasing regulatory and documentation demands placed on clinical research teams, efforts to streamline these processes are critical to the goals of adequate accrual, timely treatment, and generalizable results.
Clinical Practice Points
Increasingly, analysis of tumor tissue samples for predictive and pharmacodynamic biomarkers is incorporated into lung cancer clinical trials. Time and effort for acquiring and submitting tissue samples for clinical trials are increasing over time. Optional tissue requests are rarely submitted. Mandatory tissue requirements may delay study treatment up to several weeks. The location of archival tissue does not impact process timelines. Improved systems to expedite these processes, as well as use of blood-or imaging-based biomarkers, may help address these issues.
